Elite in Pituitary Tumor

Dr. Maria Fleseriu

Endocrinology
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
Accepting New Patients
Offers Telehealth
Elite in Pituitary Tumor
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Maria Fleseriu is an Endocrinologist in Portland, Oregon. Dr. Fleseriu and is rated as an Elite provider by MediFind in the treatment of Pituitary Tumor. Her top areas of expertise are Acromegaly, Cushing's syndrome, Cushing's disease, Pituitary Tumor, and Hormone Replacement Therapy (HRT). Dr. Fleseriu is currently accepting new patients.

Her clinical research consists of co-authoring 237 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 77 articles and participated in 3 clinical trials in the study of Pituitary Tumor.

Specialties
Endocrinology
Licenses
Internal Medicine in OR
Hospital Affiliations
Ohsu Hospital And Clinics
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Kaiser
  • EPO
  • HMO
  • POS
PacificSource
  • PPO

Locations

UNIVERSITY PROFESSIONAL SERVICES
3181 Sw Sam Jackson Park Rd, Portland, OR 97239

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drug: Osilodrostat
Study Phase: Phase 2
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

232 Total Publications

Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries.
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries.
Journal: Reviews in endocrine & metabolic disorders
Published: February 25, 2025
Similar Doctors
Elite in Pituitary Tumor
Dr. Elena Varlamov
Endocrinology
Elite in Pituitary Tumor
Dr. Elena Varlamov
Endocrinology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (0.1 mi)
503-494-8311
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Varlamov is an Endocrinologist in Portland, Oregon. Dr. Varlamov and is rated as a Distinguished provider by MediFind in the treatment of Pituitary Tumor. Her top areas of expertise are Pituitary Tumor, Acromegaly, Hypothalamic Tumor, and Prolactinoma.

Distinguished in Pituitary Tumor
Dr. Fawn Wolf
Endocrinology
Distinguished in Pituitary Tumor
Dr. Fawn Wolf
Endocrinology

Providence Health And Services Oregon

5050 Ne Hoyt St, 240 Providence Med Gr Ca, 
Portland, OR 
 (4.1 mi)
503-215-6480
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fawn Wolf is an Endocrinologist in Portland, Oregon. Dr. Wolf and is rated as an Advanced provider by MediFind in the treatment of Pituitary Tumor. Her top areas of expertise are Type 1 Diabetes (T1D), Pituitary Tumor, Diabetes Insipidus (DI), and Neurohypophyseal Diabetes Insipidus.

Advanced in Pituitary Tumor
Dr. Scott Grady
Endocrinology
Advanced in Pituitary Tumor
Dr. Scott Grady
Endocrinology

Portland Diabetes And Endocrinology

9135 Sw Barnes Rd, Suite 985, 
Portland, OR 
 (4.3 mi)
503-297-3336
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Grady is an Endocrinologist in Portland, Oregon. Dr. Grady and is rated as an Advanced provider by MediFind in the treatment of Pituitary Tumor. His top areas of expertise are Medullary Thyroid Carcinoma, Anaplastic Thyroid Cancer, Papillary Thyroid Cancer, and Thyroid Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fleseriu's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 7 Distinguished Conditions
View All 11 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile